Protalix BioTherapeutics, Inc. (PLX) is a Biotechnology company in the Healthcare sector, currently trading at $2.36. It has a SharesGrow Score of 53/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Valuation: PLX trades at a trailing Price-to-Earnings (P/E) of -26.5 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.39.
Financials: revenue is $53M, +5.9%/yr average growth. Net income is $7M (loss), growing at -78.1%/yr. Net profit margin is -12.5% (negative). Gross margin is 48.8% (-10.1 pp trend).
Balance sheet: total debt is $8M against $48M equity (Debt-to-Equity (D/E) ratio 0.17, conservative). Current ratio is 2.51 (strong liquidity). Debt-to-assets is 10.1%. Total assets: $82M.
Analyst outlook: 5 / 7 analysts rate PLX as buy (71%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 40/100 (Partial), Past 50/100 (Partial), Health 67/100 (Partial), Moat 28/100 (Fail), Future 75/100 (Pass), Income 10/100 (Fail).
